Jazz Pharmaceuticals Public
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Jazz Pharmaceuticals Public's revenues will grow 61.1% and EPS will expand 38.5%.
The average estimate for revenue is $208.7 million. On the bottom line, the average EPS estimate is $1.51.
Last quarter, Jazz Pharmaceuticals Public booked revenue of $196.2 million. GAAP reported sales were 91% higher than the prior-year quarter's $102.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
Last quarter, non-GAAP EPS came in at $1.37. GAAP EPS of $0.71 for Q1 were 48% higher than the prior-year quarter's $0.48 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the preceding quarter, gross margin was 86.9%, 680 basis points worse than the prior-year quarter. Operating margin was 38.8%, 330 basis points worse than the prior-year quarter. Net margin was 22.1%, 490 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $853.3 million. The average EPS estimate is $6.18.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 252 members out of 317 rating the stock outperform, and 65 members rating it underperform. Among 83 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 70 give Jazz Pharmaceuticals Public a green thumbs-up, and 13 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals Public is buy, with an average price target of $71.36.
- Add Jazz Pharmaceuticals Public to My Watchlist.